Van ECK Associates Corp Has $6.08 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Van ECK Associates Corp cut its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 18.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,379 shares of the specialty pharmaceutical company’s stock after selling 10,832 shares during the quarter. Van ECK Associates Corp owned about 0.08% of Jazz Pharmaceuticals worth $6,081,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. UMB Bank n.a. grew its holdings in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the period. Itau Unibanco Holding S.A. grew its holdings in shares of Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 172 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 206 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after buying an additional 704 shares during the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 350 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the transaction, the chief executive officer now owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 5,053 shares of company stock valued at $617,442. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $133.96 on Tuesday. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $138.27. The firm has a market capitalization of $8.10 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 0.92 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock’s 50-day simple moving average is $123.73 and its 200-day simple moving average is $117.41.

Analysts Set New Price Targets

A number of research firms recently weighed in on JAZZ. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. TD Cowen dropped their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $180.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.